Predicting the efficacy of immune checkpoint inhibitor therapy in Chinese patients with metastatic and/or unresectable gastric cancer using gut microbiota

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055469

Enrollment

Unknown

Registered

2022-01-10

Start date

2022-01-08

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Experimental group:Injection of PD-1/L1 immune checkpoint inhibitor drugs

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with metastatic and/or unresectable gastric cancer undergoing immunotherapy (immune checkpoint inhibitor therapy); 2. Routine fecal specimens were taken when hospitalized for treatment.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
intestinal flora;	—

Countries

China

Contacts

Public ContactGao Wei

Fujian Cancer Hospital

13960986882@163.com+86 13960986882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026